CDXS Codexis

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts.

Management will participate in a fireside chat on Monday, March 4, 2024, at 2:50 pm ET. A live webcast of the event will be available and in the Investor Relations section of the Company’s website, . A replay will be archived for 90 days following the event.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit .

For More Information

Investor Contact

Carrie McKim

(336) 608-9706

Media Contact

Lauren Musto

(650) 421-8205



EN
26/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Codexis

 PRESS RELEASE

Codexis to Report First Quarter 2024 Financial Results on May 2

Codexis to Report First Quarter 2024 Financial Results on May 2 REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the , where it will be archived for 90 days. The live call ...

 PRESS RELEASE

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical appl...

 PRESS RELEASE

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End of 2026 2024 to Focus on Securing Early Access Customers for ECO Synthesis™ Manufacturing Platform, Launch of Double-stranded RNA Ligase and Return to Growth for Pharmaceutical Manufacturing REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS...

 PRESS RELEASE

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Doub...

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company’s EvoT4™ DNA ligase. Under the terms of the deal, Codexis will receive upfront and technical milestone payments. This deal supersed...

 PRESS RELEASE

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Codexis to Participate in TD Cowen 44th Annual Health Care Conference REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts. Management will participate in a fireside chat on Monday, March 4, 2024, at 2:50 pm ET. A live webcast of the event will be available and in the Investor Relations section of the Company’s website, . A replay will be archived for 90 days following the even...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch